Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotigotine (UCB)
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Rotigotine is a non-ergoline dopamine agonist formulated as a once-daily transdermal patch for the treatment of Parkinson's disease and Restless Legs Syndrome. Developed by UCB Pharma (following the acquisition of Schwarz Pharma), it acts as a potent agonist at D1, D2, and D3 dopamine receptors, as well as various serotonin and adrenergic receptors. The transdermal delivery system provides continuous drug release over 24 hours, which helps maintain stable plasma concentrations and may reduce motor fluctuations compared to intermittent oral dosing. It is particularly noted for its efficacy in managing early morning motor impairment and sleep disturbances in patients with early-stage and advanced idiopathic Parkinson's disease.
- Brand names
- Neupro
- Other names
- rotigotine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA2B (α2B)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on rotigotine (UCB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotigotine (UCB).